Pharma ingredients have strong role to play in Kerry Group’s expansion

PHARMA ingredients may represent just 4% of Kerry Group’s business, but they can play a useful role in the company’s global expansion strategy, according to an equity report by Davy stockbrokers.

Kerry Group’s recent acquisition of Lactose India, a producer of pharma-grade lactose, will enhance its foothold in the rapidly evolving Asia Pacific marketplace. Since its acquisition of Quest in 2004, Kerry has made steady progress in marrying its food expertise with its interests in developing new outlets for the food ingredients side of its business.

Kerry has enjoyed steady growth for producing excipients, for instance, tabletting systems to carry the active ingredients in medicines. While in its infancy relative to other sides of Kerry’s business, pharma ingredients has the potential to grow significantly, according to the Davy market report.